Home/Biosimilar Atlas/Epoetin alfa and zeta/Reliance epoetin

Reliance epoetin

Epoetin alfa and zeta biosimilar developed by Not stated in the CDSCO list. Reference product Eprex (Epogen and Procrit in the United States).

Brands by market: Brand not published by CDSCO (India, import) ยท Commercial partner or holder: Reliance Biopharmaceuticals (import)
FDAnot listed
EMAnot listed
PMDAnot listed
HCnot listed
CDSCOJan 2008permitted
EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Biopharmaceuticals
Pathway
Import and marketing permission
Approved
Jan 2008
Application or permission
Import permission; bulk 31 January 2008
Indications as licensed
Anaemia due to chronic renal failure
Presentations
10,000 IU/mL PFS
Source
S013
EDE

United Arab Emirates

Not listed by EDE.

Chronology

Sources

All epoetin alfa and zeta biosimilars

Planning epoetin alfa and zeta biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.